Head and Neck Neoplasms Clinical Trial
— SupCareOfficial title:
Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study
This is a late phase II, prospective, multicenter randomized study, to assess the value of early palliative care integrated with the standard oncologic care in patients with Recurrent Metastatic (RM) Head and Neck Cancer (HNC) proposed to first line palliative systemic treatment. The study randomizes patients in a 1:1 fashion to standard oncologic care, in which the palliative care is requested as needed (reactive approach) or to early palliative care integrated with the standard oncologic care (proactive approach). Standard of Care: the oncologist will be the main referral of the patient, deciding the therapeutic approach, the assessments requested, in terms of type of exams and timing and the need of possible further support from other expertise. The oncologist will base the choices also upon the results of the Liverpool Head and Neck Patient Concern Inventory (PCI-H&N) and the patient's preferences. At the end of the first oncological visit, the physician will be asked to predict the survival of the patient. Integrated approach: Besides the Oncology visit, patient will have the palliative care expert visit and follow up. The oncologist will define the therapeutic approach and the assessments requested, in terms of type of exams and timing. The palliative care clinician and the oncologist will judge the burden of symptoms and together they will propose the suggested interventions to relief the symptoms, with a particular attention to a validated instrument (the PCI-H&N) and patient priority questionnaire's results. Stratification Factors - Institution - Performance Status (PS) (0 vs 1-2) - Presence of any caregiver at home - Type of treatment (Immunotherapy alone vs any other combination) Study duration: the total study duration is estimated at 36 months, with a total accrual time estimated to be 24 months from first patient in (FPI) and with an additional follow-up period of 12 months. End of study occurs when all patients have completed their end of study visit and the study is mature for all analyses defined in the protocol and the database has been cleaned and frozen for these analyses.
Status | Not yet recruiting |
Enrollment | 160 |
Est. completion date | December 2028 |
Est. primary completion date | April 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients over 18 years of age - Histological diagnosis of HNC of epithelial origin. Any sub-site of head and neck is eligible except endocrine tumours such as thyroid and parathyroid cancer - First diagnosis of recurrent disease and/or distant metastasis; with recurrent disease not amenable to salvage surgery or re-irradiation - Patient candidate to any first line systemic treatment - Life expectancy more than 3 months - PS Eastern Cooperative Oncology Group (ECOG) =2 - Adequate cognitive and reading abilities. - Availability of baseline scores for Emotional Functioning and Pain - Patient agrees to complete questionnaires at week 6, 15, 24 and 52 after systemic treatment start - Before patient 's enrolment, written informed consent must be given according to International Council for Harmonisation (ICH)/Good Clinical Practice (GCP), and national/local regulations. Exclusion Criteria: - Patients requiring a palliative care consultation right from the beginning of treatment - Cutaneous primary cancer - Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed and discussed with the patient before the enrolment in the study |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
European Organisation for Research and Treatment of Cancer - EORTC |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in emotional functioning and pain scores according to Item List (IL) 250 questionnaire at 15 weeks. | To assess the added value of early palliative care integrated with the standard oncologic care as measured by the difference in mean change from baseline to 15 weeks between arms in patient reported emotional functioning and pain.
Minimum = -100; Maximum = +100; higher means better outcome |
at 15 weeks | |
Secondary | Change from baseline in emotional functioning and pain scores according to Item List 250 (IL250) questionnaire at 6 weeks, 24 weeks and 52 weeks. | Evaluate the added value of early palliative care integrated with the standard oncologic care as measured by the difference in mean change from baseline at alternative timepoints between arms in patient reported emotional functioning and pain.
Minimum = -100; Maximum = +100; higher means better outcome |
at 6 weeks, 24 weeks and 52 weeks | |
Secondary | Change from baseline in the selected Health Related Quality of Life (HRQoL) scales from the Item List 250 (IL250) questionnaire at 6 weeks, 15 weeks, 24 weeks and 52 weeks | Evaluate the change from baseline in supportive patient-reported symptom and functional outcomes at 6 weeks, 15 weeks, 24 weeks and 52 weeks.
Minimum = -100; Maximum = +100; higher means better outcome |
at 6 weeks, 15 weeks, 24 weeks and 52 weeks | |
Secondary | Number of unplanned visits to emergency room or specialist visits | Evaluate the frequency of the unplanned access to emergency room or specialist visits | up to 52 weeks | |
Secondary | Hospitalization due to treatment toxicities or tumour signs/symptoms, as evaluated by number of admissions and duration | Frequency of hospitalization due to adverse effects of treatment or due to tumour symptoms/signs | up to 52 weeks | |
Secondary | Identification of the rate of patients starting a new systemic treatment in the last three months of life | Frequency of oncological treatments in last three months of life. | until 1 year from last patient enrolled | |
Secondary | Rate of patients receiving systemic treatment in the last month of life | Identification of the rate of patients receiving systemic treatment in the last month of life | until 1 year from last patient enrolled | |
Secondary | Rate of patients with a tracheostomy performed in the last 3 months of life | Identification of the rate of patients with tracheostomy performed in the last 3 months of life. | until 1 year from last patient enrolled | |
Secondary | Rate of patients with gastrostomy performed in the last 3 months of life | Identification of the rate of patients with gastrostomy performed in the last 3 months of life. | until 1 year from last patient enrolled | |
Secondary | Caregiver/family members' satisfaction (FAMcare questionnaire) at 15 weeks | Assessment of the caregiver/family members' satisfaction. Minimum = -99; Maximum = +99; higher means better outcome. | at 15 weeks | |
Secondary | Overall Survival (OS) | Overall Survival | until 1 year from last patient enrolled | |
Secondary | Prediction error of survival (defined as the difference between actual survival (AS) of patients and clinician prediction of survival (CPS)) | Accuracy of physician prediction of survival | until 1 year from last patient enrolled |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05980598 -
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02548377 -
Remote Ischemic Preconditioning in Head and Neck Cancer Reconstruction - A Randomized Controlled Trial
|
N/A | |
Active, not recruiting |
NCT02229656 -
Olaparib and Radiotherapy in Head and Neck Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Terminated |
NCT02975739 -
Feasibility of Holmium-166 Micro Brachytherapy in Head and Neck Tumors
|
N/A | |
Recruiting |
NCT00982436 -
Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01025518 -
DAHANCA 25A: Resistance Training and Dietary Supplements as Intervention for Regaining Muscle Mass Following Radiotherapy in Head and Neck Cancer Patients
|
N/A | |
Active, not recruiting |
NCT00248235 -
Resistance Exercise Training for the Shoulder and Neck Following Surgery for Head and Neck Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT00135161 -
Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer
|
Phase 1 | |
Terminated |
NCT00073450 -
Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)
|
Phase 2 | |
Not yet recruiting |
NCT06458517 -
Evaluation of Two Methods of Administration of Photobiomodulation in the Context of the Prevention and Treatment of Mucositis Induced by Radiotherapy, During the Treatment of Head and Neck Cancers
|
N/A | |
Completed |
NCT05269342 -
Nurse-led Exercise Improves Shoulder Pain, Shoulder Disability, and Quality of Life in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05544136 -
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
|
Phase 2 | |
Terminated |
NCT03286972 -
PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning
|
||
Recruiting |
NCT04435938 -
A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
Recruiting |
NCT03678649 -
A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC
|
Phase 2 | |
Recruiting |
NCT03975465 -
EMST and Swallowing in Long-Term Survivors of HNCA
|
N/A | |
Completed |
NCT03292250 -
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
|
Phase 2 | |
Completed |
NCT06446570 -
Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
|
Phase 2 | |
Completed |
NCT02284802 -
Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy
|
N/A |